Hughes DA - Search Results

1

Transfer of high cost drugs to NICE risks fragmentation of care of rare diseases.

Hendriksz CJ, Hughes DA, Mehta AB, Wraith JE, Jones SE, Ramaswami U, Deegan P, Lachmann R, Murphy E, Hiwot T, Vijay SV, Stewart F, Cleary M. Hendriksz CJ, et al. Among authors: hughes da. BMJ. 2012 Aug 24;345:e5727. doi: 10.1136/bmj.e5727. BMJ. 2012. PMID: 22923539 No abstract available.

2

Vascular complications of Fabry disease: enzyme replacement and other therapies.

Hughes DA, Mehta AB. Hughes DA, et al. Acta Paediatr Suppl. 2005 Mar;94(447):28-33; discussion 9-10. doi: 10.1111/j.1651-2227.2005.tb02107.x. Acta Paediatr Suppl. 2005. PMID: 15895709 Review.

3

Depression in adults with Fabry disease: a common and under-diagnosed problem.

Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Cole AL, et al. Among authors: hughes da. J Inherit Metab Dis. 2007 Nov;30(6):943-51. doi: 10.1007/s10545-007-0708-6. Epub 2007 Nov 12. J Inherit Metab Dis. 2007. PMID: 17994284

4

Gaucher disease and pregnancy.

Mamopoulos AM, Hughes DA, Tuck SM, Mehta AB. Mamopoulos AM, et al. Among authors: hughes da. J Obstet Gynaecol. 2009 Apr;29(3):240-2. doi: 10.1080/01443610902754398. J Obstet Gynaecol. 2009. PMID: 19358035 Free article. No abstract available.

5

Age adjusting severity scores for Anderson-Fabry disease.

Hughes DA, Ramaswami U, Barba Romero MÁ, Deegan P; FOS Investigators. Hughes DA, et al. Mol Genet Metab. 2010 Oct-Nov;101(2-3):219-27. doi: 10.1016/j.ymgme.2010.06.002. Epub 2010 Jun 22. Mol Genet Metab. 2010. PMID: 20691627

6

Potential biomarkers of osteonecrosis in Gaucher disease.

Pavlova EV, Deegan PB, Tindall J, McFarlane I, Mehta A, Hughes D, Wraith JE, Cox TM. Pavlova EV, et al. Blood Cells Mol Dis. 2011 Jan 15;46(1):27-33. doi: 10.1016/j.bcmd.2010.10.010. Epub 2010 Nov 13. Blood Cells Mol Dis. 2011. PMID: 21075651

7

The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.

Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, Klinger L, Hughes D, Waldek S, Lachmann R, Mehta A, Vellodi A, Logan S. Wyatt K, et al. Health Technol Assess. 2012;16(39):1-543. doi: 10.3310/hta16390. Health Technol Assess. 2012. PMID: 23089251 Free article.

8

Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists.

Thomas AS, Mehta AB, Hughes DA. Thomas AS, et al. Among authors: hughes da. Blood Cells Mol Dis. 2013 Mar;50(3):212-7. doi: 10.1016/j.bcmd.2012.11.004. Epub 2012 Dec 6. Blood Cells Mol Dis. 2013. PMID: 23219328

9

A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.

Hughes DA, Deegan PB, Milligan A, Wright N, Butler LH, Jacobs A, Mehta AB. Hughes DA, et al. Mol Genet Metab. 2013 Jul;109(3):269-75. doi: 10.1016/j.ymgme.2013.04.015. Epub 2013 Apr 28. Mol Genet Metab. 2013. PMID: 23702393 Clinical Trial.

10

Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease.

Reed M, Baker RJ, Mehta AB, Hughes DA. Reed M, et al. Among authors: hughes da. Blood Cells Mol Dis. 2013 Oct;51(3):185-94. doi: 10.1016/j.bcmd.2013.04.006. Epub 2013 May 23. Blood Cells Mol Dis. 2013. PMID: 23707505

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters